Found: 8
Select item for more details and to access through your institution.
CCR2 modulates inflammatory and metabolic effects of high-fat feeding.
- Published in:
- 2006
- By:
- Publication type:
- journal article
Validation of protein arginine methyltransferase 5 (PRMT5) as a candidate therapeutic target in the spontaneous canine model of non-Hodgkin lymphoma.
- Published in:
- PLoS ONE, 2021, v. 16, n. 5, p. 1, doi. 10.1371/journal.pone.0250839
- By:
- Publication type:
- Article
Ruxolitinib: a targeted treatment option for patients with tpolycythemia vera.
- Published in:
- Blood & Lymphatic Cancer: Targets & Therapy, 2016, v. 6, p. 7, doi. 10.2147/BLCTT.S101185
- By:
- Publication type:
- Article
Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes.
- Published in:
- International Journal of General Medicine, 2014, v. 7, p. 89, doi. 10.2147/IJGM.S51800
- By:
- Publication type:
- Article
Preclinical Evaluation of Local JAK1 and JAK2 Inhibition in Cutaneous Inflammation.
- Published in:
- Journal of Investigative Dermatology, 2011, v. 131, n. 9, p. 1838, doi. 10.1038/jid.2011.140
- By:
- Publication type:
- Article
Evaluating the serial use of the Myelofibrosis Symptom Assessment Form for measuring symptomatic improvement: performance in 87 myelofibrosis patients on a JAK1 and JAK2 inhibitor (INCB018424) clinical trial.
- Published in:
- 2011
- By:
- Publication type:
- journal article
Evaluating the serial use of the myelofibrosis symptom assessment form for measuring symptomatic improvement.
- Published in:
- Cancer (0008543X), 2011, v. 117, n. 21, p. 4869, doi. 10.1002/cncr.26129
- By:
- Publication type:
- Article
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis.
- Published in:
- British Journal of Haematology, 2013, v. 161, n. 4, p. 508, doi. 10.1111/bjh.12274
- By:
- Publication type:
- Article